S
2.77
-0.26 (-8.58%)
| Previous Close | 3.03 |
| Open | 3.01 |
| Volume | 2,533,056 |
| Avg. Volume (3M) | 2,493,540 |
| Market Cap | 739,221,312 |
| Price / Book | 5.31 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Diluted EPS (TTM) | -0.880 |
| Total Debt/Equity (MRQ) | 43.67% |
| Current Ratio (MRQ) | 3.40 |
| Operating Cash Flow (TTM) | -206.18 M |
| Levered Free Cash Flow (TTM) | -118.45 M |
| Return on Assets (TTM) | -23.84% |
| Return on Equity (TTM) | -71.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Sana Biotechnology, Inc. | Bearish | Mixed |
AIStockmoo Score
0.7
| Analyst Consensus | -0.5 |
| Insider Activity | 3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 2.0 |
| Average | 0.70 |
|
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 8.46% |
| % Held by Institutions | 89.37% |
| 52 Weeks Range | ||
| Median | 7.00 (152.71%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 04 Mar 2026 | 7.00 (152.71%) | Buy | 3.82 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BISHOP HANS EDGAR | 3.22 | - | 7,763 | 24,997 |
| Aggregate Net Quantity | 7,763 | |||
| Aggregate Net Value ($) | 24,997 | |||
| Aggregate Avg. Buy ($) | 3.22 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BISHOP HANS EDGAR | Director | 06 Apr 2026 | Acquired (+) | 7,763 | 3.22 | 24,997 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |